Literature DB >> 22473987

Malignant melanoma of the head and neck: a multi-institutional retrospective analysis of cases in northern Japan.

Kiyoto Shiga1, Takenori Ogawa, Toshimitsu Kobayashi, Seigo Ueda, Atsushi Kondo, Atsushi Nanba, Shigeru Kuwashima, Yukinori Asada, Seigo Suzuki, Tatsumi Nagahashi, Masafumi Takahashi, Masahiro Suzuki, Akihiro Ishida, Kenichi Watanabe, Yasuaki Harabuchi, Tetsuo Himi, Hideichi Sinkawa, Hiroaki Sato, Shigeru Saijo, Satoshi Fukuda, Katsuhiko Tanaka, Kazuo Ishikawa, Koichi Omori, Masaru Aoyagi, Sho Hashimoto.   

Abstract

BACKGROUND: Mucosal melanoma of the head and neck is rare and is associated with a poor prognoses because of locoregional failure and distant metastasis. The aim of our study was to review the characteristics of these patients in northern Japan and to analyze their outcomes.
METHODS: The medical records of 94 patients who had been provided initial treatment in 12 institutes from 1998 to 2007 were reviewed.
RESULTS: When the 5-year overall survival rates of patients were evaluated, we found that the survival rates of patients treated by chemotherapy were significantly lower than those of patients treated by surgery or radiation. The survival rates of the single-treatment modality, 2-modality, and ≥3-modality groups were 23.4%, 38.0%, and 33.6%, respectively.
CONCLUSION: Our results suggest that patients who underwent combined treatment had better prognoses. However, we found that chemotherapy had no additional survival benefits.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22473987     DOI: 10.1002/hed.21984

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

Review 1.  Primary amelanotic mucosal melanoma of the oronasal region: report of two new cases and literature review.

Authors:  Luiz Fernando Barbosa de Paulo; João Paulo Silva Servato; Roberta Rezende Rosa; Maiolino Thomaz Fonseca Oliveira; Paulo Rogério de Faria; Sindeval José da Silva; Sergio Vitorino Cardoso; Adriano Mota Loyola
Journal:  Oral Maxillofac Surg       Date:  2015-05-03

2.  Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma.

Authors:  Moran Amit; Samantha Tam; Ahmed S Abdelmeguid; Michael E Kupferman; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna
Journal:  J Neurol Surg B Skull Base       Date:  2017-07-31

Review 3.  Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma.

Authors:  Moran Amit; Shorook Na'ara; Ehab Y Hanna
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

4.  Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013.

Authors:  Gaber Plavc; Jasna But-Hadžić; Aleksandar Aničin; Boštjan Lanišnik; Vojislav Didanović; Primož Strojan
Journal:  Radiat Oncol       Date:  2016-10-14       Impact factor: 3.481

5.  Primary amelanotic melanoma of the mandibular gingiva.

Authors:  Byeong Jun Kim; Hyeong Seop Kim; Yong Joon Chang; Kee Hwan Kwon; Seong Jin Cho
Journal:  Arch Craniofac Surg       Date:  2020-04-20

6.  Particle radiotherapy with carbon ion beams.

Authors:  Tatsuya Ohno
Journal:  EPMA J       Date:  2013-03-04       Impact factor: 6.543

7.  Comparative study between two different staging systems (AJCC TNM VS BALLANTYNE'S) for mucosal melanomas of the Head & Neck.

Authors:  K Luna-Ortiz; M Aguilar-Romero; V Villavicencio-Valencia; E Zepeda-Castilla; H Vidrio-Morgado; N Peteuil; A Mosqueda-Taylor
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-07-01

8.  Study of the physicochemical properties of drugs suitable for administration using a lymphatic drug delivery system.

Authors:  Ryoichi Fukumura; Ariunbuyan Sukhbaatar; Radhika Mishra; Maya Sakamoto; Shiro Mori; Tetsuya Kodama
Journal:  Cancer Sci       Date:  2021-03-16       Impact factor: 6.716

9.  Intranodal delivery of modified docetaxel: Innovative therapeutic method to inhibit tumor cell growth in lymph nodes.

Authors:  Ariunbuyan Sukhbaatar; Shiro Mori; Tetsuya Kodama
Journal:  Cancer Sci       Date:  2022-02-14       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.